Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456982 | 1.00 | MAPT (0.46) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL9246536 | 1.00 | MAPT (0.46) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL9030000 | 0.88 | MAPT (0.47) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL8830256 | 0.86 | TSHR (0.43) | MAPTL3MBTL1MAPK1LMNAPHGDH | |
| SCHEMBL8830303 | 0.84 | MAPT (0.42) | MAPTNPC1RAB9ALMNAMEN1 | |
| SCHEMBL9068299 | 0.83 | MAPT (0.45) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL8916681 | 0.80 | ITGB1 (0.44) | MAPTMAPK1NPC1RAB9ALMNA | |
| SCHEMBL14440013 | 0.79 | CXCL8 (0.43) | MAPTMAPK1LMNAALDH1A1HTT | |
| SCHEMBL9032150 | 0.79 | LMNA (0.49) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL8974822 | 0.79 | KMT2A (0.37) | MAPTL3MBTL1MAPK1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | claimed |
| US-9938528-B2 | Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-04-10 | — | — | US | claimed |
| US-20170342411-A1 | Methods and Pharmaceutical Compositions for Treating Human Immunodeficiency Virus Type 1 (HIV-1) Infections | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2017-11-30 | — | — | US | claimed |
| EP-3230455-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092041-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-16 | — | — | WO | claimed |
| US-7037917-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| US-6962916-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-08 | — | — | US | claimed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | claimed |
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. | 2003-10-23 | — | — | US | claimed |
| EP-0684818-B1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA NV (BE) | 1999-05-06 | — | — | EP | claimed |
| US-5684049-A | HIV-inhibiting benzeneacetamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-04 | — | — | US | claimed |
| EP-0538301-B1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1996-10-30 | — | — | EP | claimed |
| US-5556886-A | VIRICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-17 | — | — | US | claimed |
| EP-0684818-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | claimed |
| CN-1107835-A | A process for preparing pharmaceutical composition showing properties in against human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-06 | — | — | CN | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| CN-1028990-C | Process for preparing phenylacetamide derivatives for inhibiting human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-06-21 | — | — | CN | claimed |
| WO-1994018963-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-3528791-B1 | DISPERSIBLE COMPOSITIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4248947-A2 | DISPERSIBLE COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-27 | — | — | EP | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-1663240-B2 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-03-01 | — | — | EP | disclosed |
| EP-3808743-B1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| EP-1632232-B3 | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220008333-A1 | DISPERSIBLE COMPOSITIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-01-13 | — | — | US | disclosed |
| US-20220008417-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-13 | — | — | US | disclosed |
| US-11065198-B2 | Dispersible compositions | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-20 | — | — | US | disclosed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-05 | — | — | US | disclosed |
| US-20200171027-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-06-04 | — | — | US | disclosed |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| EP-2298761-B1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-25 | — | — | EP | disclosed |
| US-20200069579-A1 | DISPERSIBLE COMPOSITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-05 | — | — | US | disclosed |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| EP-3528791-A1 | DISPERSIBLE COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-28 | — | — | EP | disclosed |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20190216807-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-07-18 | — | — | US | disclosed |
| US-10077270-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-18 | — | — | US | disclosed |
| US-10072015-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-11 | — | — | US | disclosed |
| US-20180244632-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| WO-2018077815-A1 | DISPERSIBLE COMPOSITIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180116964-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-9938528-B2 | Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20180036427-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV INFECTION | UNIVERSITÉ DE BORDEAUX (FR) | 2018-02-08 | — | — | US | disclosed |
| US-20180016281-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-18 | — | — | US | disclosed |
| US-20180009819-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-11 | — | — | US | disclosed |
| EP-3265566-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV INFECTION | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2018-01-10 | — | — | EP | disclosed |
| US-20170342411-A1 | Methods and Pharmaceutical Compositions for Treating Human Immunodeficiency Virus Type 1 (HIV-1) Infections | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9802943-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-31 | — | — | US | disclosed |
| EP-3230455-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20170191059-A1 | NUCLEIC ACIDS ACTING AS DECOYS FOR THE TREATMENT OF LENTIVIRUS INFECTION | Universite de Bordeaux (FR) | 2017-07-06 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20170100398-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2017-04-13 | — | — | US | disclosed |
| EP-3146048-A2 | NUCLEIC ACIDS ACTING AS DECOYS FOR THE TREATMENT OF LENTIVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-29 | — | — | EP | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-20160355519-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-12-08 | — | — | US | disclosed |
| US-9487518-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-08 | — | — | US | disclosed |
| EP-1597237-B1 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-27 | — | — | EP | disclosed |
| WO-2016092041-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015177331-A2 | NUCLEIC ACIDS ACTING AS DECOYS FOR THE TREATMENT OF LENTIVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-11-26 | — | — | WO | disclosed |
| EP-1282607-B1 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150283135-A1 | Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors | JANSEN SCIENCES IRELAND UC (IE) | 2015-10-08 | — | — | US | disclosed |
| EP-2603587-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV-1 INFECTIONS | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2015-10-07 | — | — | EP | disclosed |
| EP-1282606-B1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-22 | — | — | EP | disclosed |
| EP-1663240-B1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-22 | — | — | EP | disclosed |
| US-8946248-B2 | HIV inhibiting 5-substituted pyrimidines | JANSSEN R&D IRELAND (IR) | 2015-02-03 | — | — | US | disclosed |
| EP-1853567-B1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE OXIDE DERIVATIVES | JANSSEN R & D IRELAND (IE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140349971-A1 | Combinations of A Pyrimidine Containing NNRTI with RT Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | JANSSEN PHARMACEUTICA NV (NL) | 2014-11-20 | — | — | US | disclosed |
| US-8841310-B2 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | JANSSEN R & D IRELAND (IE) | 2014-09-23 | — | — | US | disclosed |
| US-8828982-B2 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-09 | — | — | US | disclosed |
| EP-1807430-B1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN R & D IRELAND (IE) | 2014-07-23 | — | — | EP | disclosed |
| US-8575342-B2 | HIV inhibiting 5-heterocyclyl pyrimidines | TIBOTECH PHARMACEUTICALS LTD. (IE) | 2013-11-05 | — | — | US | disclosed |
| EP-1797050-B1 | HIV INHIBITING 1.2.4-TRIAZIN-6-ONE DERIVATES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8530655-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20130156791-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS | INSTITUT PASTEUR (FR) | 2013-06-20 | — | — | US | disclosed |
| EP-2603587-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-06-19 | — | — | EP | disclosed |
| CN-101027288-B | HIV inhibiting 5-substituted pyrimidines | TIBOTEC PHARM LTD | 2013-04-17 | — | — | CN | disclosed |
| US-20120190697-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-07-26 | — | — | US | disclosed |
| CN-102558070-A | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | TIBOTEC PHARM LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-101133038-B | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARM LTD | 2012-06-27 | — | — | CN | disclosed |
| US-8153640-B2 | Reverse transcriptase inhibitors; use against HIV with drug resistance to NNRTI's (Non Nucleoside Reverse Transcriptase Inhibitor drugs); Diaryl Pyrrolo(2,3-d)pyrimidines, diaryl purines, diaryl v-triazolo(4,5-d)pyrimidines | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-10 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| EP-1789139-B1 | FUMARATE OF 4-((4-((4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL AMINO -2-PYRIMIDINYL AMINO BENZONITRILE | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-8119801-B2 | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-02-21 | — | — | US | disclosed |
| WO-2012019991-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-02-16 | — | — | WO | disclosed |
| EP-1797047-B1 | HIV INHIBITING 5-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2012-01-25 | — | — | EP | disclosed |
| US-8101629-B2 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-24 | — | — | US | disclosed |
| EP-1838709-B1 | 1,5,6-SUBSTITUTED-2-OXO-3-CYANO-1,6A-DIAZA-TETRAHYDRO-FLUORANTHENES AS ANTI-INFECTIVE AGENTS | TIBOTEC PHARM LTD (IE) | 2011-12-21 | — | — | EP | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| EP-2388249-A1 | HIV inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives | Tibotec Pharmaceuticals (IE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | CORTE BART DE | 2011-10-27 | — | — | US | disclosed |
| US-20110255174-A1 | Display Device with an Optical Combiner Corrected for Chromatic Aberrations | THALES (FR) | 2011-10-20 | — | — | US | disclosed |
| US-8036861-B2 | Using phenotypic marker concentration as evaluative tool in measuring propagation progression of viral nucleotide sequences; diagnosing microorganismal infection | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-11 | — | — | US | disclosed |
| US-8026248-B2 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-27 | — | — | US | disclosed |
| US-8026245-B2 | HIV replication inhibiting purine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-27 | — | — | US | disclosed |
| EP-1853568-B1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO)PYRIMIDINE DERIVATIVES | TIBOTEC PHARM LTD (IE) | 2011-09-07 | — | — | EP | disclosed |
| US-8003789-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-08-23 | — | — | US | disclosed |
| EP-1797069-B1 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-1797048-B1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLIC SUBSTITUTED PYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-1419152-B1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-07-07 | — | — | US | disclosed |
| US-20110150996-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE | STEVENS PAUL THEODOOR AGNES | 2011-06-23 | — | — | US | disclosed |
| US-7956063-B2 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| EP-1632232-B1 | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-11 | — | — | EP | disclosed |
| US-7935710-B2 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-05-03 | — | — | US | disclosed |
| US-7935711-B2 | HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-05-03 | — | — | US | disclosed |
| US-7923554-B2 | HIV inhibiting 1,2,4-triazin-6-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-12 | — | — | US | disclosed |
| EP-2298761-A1 | HIV inhibiting pyrimidines derivatives | Janssen Pharmaceutica NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| EP-1245567-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-1668011-B1 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-7887845-B2 | Particle of a solid dispersion composed of a water soluble polymer and etravirine or salt thereof; etravirine FDA Orange book listed patent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20110008434-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | GUILLEMONT JEROME EMILE GEORGES | 2011-01-13 | — | — | US | disclosed |
| US-7763631-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| EP-1858861-B1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100121060-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-05-13 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100029591-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20100009341-A1 | METHODS AND MEANS FOR ASSESSING HIV GAG/PROTEASE INHIBITOR THERAPY | TIBOTEC BVBA (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-1270560-B1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-13 | — | — | EP | disclosed |
| US-7638522-B2 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| US-20090215804-A1 | FUMARATE OF 4- [[4- [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL)AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-27 | — | — | US | disclosed |
| US-20090181993-A1 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2009-07-16 | — | — | US | disclosed |
| US-20090124644-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| EP-1946111-B1 | METHOD AND MEANS FOR DETERMINING THE REPLICATION RATE OF A VIRAL POPULATION | TIBOTEC PHARM LTD (IE) | 2009-05-13 | — | — | EP | disclosed |
| US-7531548-B2 | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2009-05-12 | — | — | US | disclosed |
| US-7514427-B2 | 1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-inflective agents | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2009-04-07 | — | — | US | disclosed |
| US-20090012092-A1 | Hiv Inhibiting 1,2,4-Triazin-6-One Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012108-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | GUILLEMONT JEROME EMILE | 2009-01-08 | — | — | US | disclosed |
| EP-2010680-A2 | METHODS AND MEANS FOR ASSESSING HIV GAG/PROTEASE INHIBITOR THERAPY | Tibotec Pharmaceuticals Ltd. (IE) | 2009-01-07 | — | — | EP | disclosed |
| US-7449575-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA, INC. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-20080262007-A1 | Hiv Inhibiting 5-Substituted Pyrimidines | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
| US-20080220412-A1 | Method and Means for Determining the Replication Rate of a Viral Population | JANSSEN SCIENCES IRELAND UC (IE) | 2008-09-11 | — | — | US | disclosed |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | TIBOTEC BVBA (BE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200435-A1 | 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile with nucleoside and/or nucleotide reverse transcriptase inhibitors; prevention of HIV transmission; pharmacokinetic profile allowing once daily dosing | TIBOTEC PHARMACEUTICALS LTD., A CORPORATION | 2008-08-21 | — | — | US | disclosed |
| US-20080194602-A1 | Hiv Inhibiting 2-(4-Cyanophenylamino) Pyrimidine Oxide Derivatives | SONY CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1597242-B1 | HIV INHIBITING 1,2,4-TRIAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1946111-A1 | METHOD AND MEANS FOR DETERMINING THE REPLICATION RATE OF A VIRAL POPULATION | Tibotec Pharmaceuticals Ltd. (IE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080167296-A1 | 1,5,6,-Substituted-2-Oxo-3-Cyano-1,6a-Diaza-Tetrahydro-Fluoranthenes as Anti-Infective Agents | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080085907-A1 | Hiv Inhibiting Bicyclic Pyrimdine Derivatives | JANSSEN-CILAG (FR) | 2008-04-10 | — | — | US | disclosed |
| CN-101133038-A | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARM LTD (IE) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858861-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853568-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-14 | — | — | EP | disclosed |
| EP-1853567-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE OXIDE DERIVATIVES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007118849-A2 | METHODS AND MEANS FOR ASSESSING HIV GAG/PROTEASE INHIBITOR THERAPY | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1505980-B1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARM LTD (IE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007114978-A2 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND PA-457 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1838709-A2 | 1,5,6-SUBSTITUTED-2-OXO-3-CYANO-1,6A-DIAZA-TETRAHYDRO-FLUORANTHENES AS ANTI-INFECTIVE AGENTS | Tibotec Pharmaceuticals Ltd. (IE) | 2007-10-03 | — | — | EP | disclosed |
| US-7276510-B2 | HIV replication inhibitors | JANSSEN PHARMACEUTICA, INC. (BE) | 2007-10-02 | — | — | US | disclosed |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-09-06 | — | — | US | disclosed |
| CN-101027288-A | HIV inhibiting 5-substituted pyrimidines | TIBOTEC PHARM LTD (IE) | 2007-08-29 | — | — | CN | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| EP-1819348-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND GW695634 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1819333-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND GW873140 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1819335-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND SCH-417690 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1814549-A2 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND UK-427, 857 | Boehringer Ingelheim International GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1814548-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND REVERSET | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1814547-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND DARUNAVIR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1812069-A2 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND ETRAVIRINE | Boehringer Ingelheim International GmbH (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1370265-B1 | HIV INHIBITING PYRAZINONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807430-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-07-18 | — | — | EP | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1797050-A1 | HIV INHIBITING 1.2.4-TRIAZIN-6-ONE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797069-A2 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797048-A2 | HIV INHIBITING 5-CARBO- OR HETEROCYCLIC SUBSTITUTED PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797047-A1 | HIV INHIBITING 5-SUBSTITUTED PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1789139-A1 | FUMARATE OF 4-((4-((4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL|AMINO|-2-PYRIMIDINYL|AMINO|BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007042568-A1 | METHOD AND MEANS FOR DETERMINING THE REPLICATION RATE OF A VIRAL POPULATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-04-19 | — | — | WO | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| US-20060293330-A1 | Hiv replication inhibiting purine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-20060252764-A1 | HIV inhibiting pyrimidines derivatives | GUILLEMONT JEROME E G | 2006-11-09 | — | — | US | disclosed |
| US-7125879-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| US-7115608-B2 | Pyridinone and pyridinethione derivatives having HIV inhibiting properties | CENTRE NATIONAL DE LA RECHERCHE SCHENTIFIQUE (FR) | 2006-10-03 | — | — | US | disclosed |
| WO-2006094930-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-09-14 | — | — | WO | disclosed |
| US-7105522-B2 | HIV inhibiting pyrazinone derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-12 | — | — | US | disclosed |
| US-20060189614-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PAUL A | 2006-08-24 | — | — | US | disclosed |
| WO-2006087387-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE OXIDE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006079656-A1 | HIV INHIBITING 2-( 4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-08-03 | — | — | WO | disclosed |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-27 | — | — | US | disclosed |
| US-20060160859-A1 | Method for treating HIV infection through co-administration of tipranavir and GW873140 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006072636-A2 | 1, 5, 6-SUBSTITUTED-2-OXO-3-CYANO-1, 6A-DIAZA-TETRAHYDRO-FLUORANTHENES AS ANTI-INFECTIVE AGENTS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060142344-A1 | Method for treating HIV infection through co-administration of tipranavir and GW695634 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060135562-A1 | Method for treating HIV infection through co-administration of tipranavir and darunavir | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060135563-A1 | Method for treating HIV infection through co-administration of tipranavir and SCH-417690 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060127487-A1 | Antiviral compositions | VERRECK GEERT | 2006-06-15 | — | — | US | disclosed |
| US-20060128733-A1 | Method for treating HIV infection through co-administration of tipranavir and reverset | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1668011-A2 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006060177-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND GW873140 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060159-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND GW695634 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060175-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND SCH-417690 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122220-A1 | Method for treating HIV infection through co-administration of tipranavir and UK-427,857 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006055455-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND DARUNAVIR | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006055660-A2 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND UK-427, 857 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006055754-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND REVERSET | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111379-A1 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006052373-A2 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND ETRAVIRINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | WO | disclosed |
| US-20060106043-A1 | Method for treating HIV infection through co-administration of tipranavir and etravirine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006045828-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-05-04 | — | — | WO | disclosed |
| US-7037917-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-7034019-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-25 | — | — | US | disclosed |
| WO-2006035067-A2 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035069-A1 | HIV INHIBITING 5-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035068-A2 | HIV INHIBITING 5-CARBO- OR HETEROCYCLIC SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| US-7015221-B2 | 2,4-disubstituted triazine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-21 | — | — | US | disclosed |
| US-20060049177-A1 | Induction heating cooker | LG ELECTRONICS INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006024668-A1 | HYDROCHLORIDE OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL] AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024667-A1 | FURAMATE OF 4-( (4-( (4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL)AMINO)-2-PYRIMIDINYL)AMINO)BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1632232-A1 | Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006015985-A1 | HIV INHIBITING 1,2,4-TRIAZIN-6-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | disclosed |
| US-20060009474-A1 | Prodrugs of HIV replication inhibiting pyrimidines | KUKLA MICHAEL J | 2006-01-12 | — | — | US | disclosed |
| EP-1129079-B1 | 2,4-DISUBSTITUDED TRIAZINE DERIVATIVES WITH ANTI HIV ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-04 | — | — | EP | disclosed |
| US-20050288278-A1 | HIV replication inhibiting pyrimidines | CORTE BART DE | 2005-12-29 | — | — | US | disclosed |
| US-20050277641-A1 | 2,4-DISUBSTITUTED TRIAZINE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. | 2005-12-15 | — | — | US | disclosed |
| EP-1597237-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-23 | — | — | EP | disclosed |
| US-6962916-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-08 | — | — | US | disclosed |
| US-20050197354-A1 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | ANDRIES KOENRAAD JOZEF L M (BE) | 2005-09-08 | — | — | US | disclosed |
| US-20050192305-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF L M (BE) | 2005-09-01 | — | — | US | disclosed |
| CN-1214013-C | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2005-08-10 | — | — | CN | disclosed |
| CN-1207290-C | 2, 4-disubstituted triazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-22 | — | — | CN | disclosed |
| US-6903213-B2 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2005-06-07 | — | — | US | disclosed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | disclosed |
| US-6878717-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| WO-2005028479-A2 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-31 | — | — | WO | disclosed |
| US-6858609-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-22 | — | — | US | disclosed |
| EP-1505980-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | Tibotec Pharmaceuticals Ltd. (IE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040229847-A1 | Pyridinone and pyridinethione derivatives having hiv inhibiting properties | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-11-18 | — | — | US | disclosed |
| US-20040198739-A1 | Prevention reproduction of virus | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004069812-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | WO | disclosed |
| US-6774235-B2 | HAVING HIV REPLICATION INHIBITING PROPERTIES. | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-10 | — | — | US | disclosed |
| US-20040102456-A1 | Hiv inhibiting pyrazinone derivatives | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-05-27 | — | — | US | disclosed |
| EP-1419152-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-19 | — | — | EP | disclosed |
| EP-0834507-B1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2004-05-19 | — | — | EP | disclosed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | disclosed |
| EP-1370265-A1 | HIV INHIBITING PYRAZINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003094920-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-20 | — | — | WO | disclosed |
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. | 2003-10-23 | — | — | US | disclosed |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030171374-A1 | HIV replication inhibitors | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2003-09-11 | — | — | US | disclosed |
| EP-0945443-B9 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030114472-A1 | Viricides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1318995-A2 | PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-06-18 | — | — | EP | disclosed |
| US-20030083317-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2003-05-01 | — | — | US | disclosed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2003016306-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-02-27 | — | — | WO | disclosed |
| EP-1282607-A2 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-02-12 | — | — | EP | disclosed |
| EP-0945443-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1270560-A1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002078708-A1 | HIV INHIBITING PYRAZINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-10 | — | — | WO | disclosed |
| US-20020147181-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PAUL A J (BE) | 2002-10-10 | — | — | US | disclosed |
| EP-1245567-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-02 | — | — | EP | disclosed |
| US-6440986-B2 | VIRICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2002-08-27 | — | — | US | disclosed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | disclosed |
| EP-1225874-A1 | ANTIVIRAL COMPOSITIONS | Janssen Pharmaceutica N.V. (BE) | 2002-07-31 | — | — | EP | disclosed |
| US-6380194-B1 | FOR TREATMENT OF SUBJECTS SUFFERING FROM HIV INFECTION | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-30 | — | — | US | disclosed |
| US-6372729-B1 | TREATMENT OF VIRAL DISEASES SUCH AS AIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-16 | — | — | US | disclosed |
| WO-2002024650-A2 | PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-03-28 | — | — | WO | disclosed |
| CN-1325387-A | 2,4-disubstituted triazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2001-12-05 | — | — | CN | disclosed |
| WO-2001085699-A2 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-15 | — | — | WO | disclosed |
| CN-1322198-A | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-14 | — | — | CN | disclosed |
| EP-1129079-A2 | 2,4-DISUBSTITUDED TRIAZINE DERIVATIVES WITH ANTI HIV ACTIVITY | Janssen Pharmaceutica N.V. (BE) | 2001-09-05 | — | — | EP | disclosed |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2001-08-02 | — | — | US | disclosed |
| WO-2001022938-A1 | ANTIVIRAL COMPOSITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-05 | — | — | WO | disclosed |
| US-6197779-B1 | VIRICIDE | JANSSEN PHARMACEUTICA, INC. | 2001-03-06 | — | — | US | disclosed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | disclosed |
| EP-1002795-A1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000027828-A2 | 2,4-DISUBSTITUTED TRIAZINE DERIVATIVES WITH ANTI HIV ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027825-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945442-A1 | Trisubstituted pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945447-A1 | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| US-5948786-A | BLOCKING TUMOR NECROSIS FACTOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0684818-B1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA NV (BE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0834507-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-08 | — | — | EP | disclosed |
| US-5684049-A | HIV-inhibiting benzeneacetamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-04 | — | — | US | disclosed |
| EP-0538301-B1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1996-10-30 | — | — | EP | disclosed |
| US-5556886-A | VIRICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-17 | — | — | US | disclosed |
| EP-0684818-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | disclosed |
| CN-1107835-A | A process for preparing pharmaceutical composition showing properties in against human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-06 | — | — | CN | disclosed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| CN-1028990-C | Process for preparing phenylacetamide derivatives for inhibiting human immunodeficiency virus | JANSSEN PHARMACEUTICA NV (BE) | 1995-06-21 | — | — | CN | disclosed |
| WO-1994018963-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0538301-A1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES. | JANSSEN PHARMACEUTICA NV (BE) | 1993-04-28 | — | — | EP | disclosed |
| CN-1058958-A | HIV inhibiting phenylacetamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1992-02-26 | — | — | CN | disclosed |
| WO-1992000952-A1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |
| WO-1992000952-A1 | HIV-INHIBITING BENZENEACETAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | MAPT 4642/4885L3MBTL1 1702/4885MAPK1 1044/4885 |
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | MAPT 3289/4885L3MBTL1 3001/4885MAPK1 3314/4885 |
| US-20200069579-A1 | DISPERSIBLE COMPOSITIONS | VPS35, RAB35, RAB6A | MAPT 478/4885L3MBTL1 3932/4885MAPK1 2014/4885 |
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | CCR1, CCR6, CCR5 | MAPT 3470/4885L3MBTL1 2697/4885MAPK1 826/4885 |
| US-20090012092-A1 | Hiv Inhibiting 1,2,4-Triazin-6-One Derivatives | NCOR1, NR1H3, NCOA3 | MAPT 4232/4885L3MBTL1 740/4885MAPK1 1804/4885 |
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | RRM2B, CCNO, RRM2 | MAPT 4242/4885L3MBTL1 539/4885MAPK1 2888/4885 |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885L3MBTL1 539/4885MAPK1 2888/4885 |
| US-20020147181-A1 | Substituted diamino-1,3,5-triazine derivatives | CCR1, CCR6, CCR5 | MAPT 3230/4885L3MBTL1 2352/4885MAPK1 1074/4885 |
| US-20060135563-A1 | Method for treating HIV infection through co-administration of tipranavir and SCH-417690 | SAMHD1, VPS51, CCR5 | MAPT 227/4885L3MBTL1 2440/4885MAPK1 4267/4885 |
| US-20220008333-A1 | DISPERSIBLE COMPOSITIONS | VPS35, RAB35, RAB6A | MAPT 478/4885L3MBTL1 3932/4885MAPK1 2014/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | MAPT 3887/4885L3MBTL1 3825/4885MAPK1 922/4885 |
| US-20090012108-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | CLIC4, HCN4, SCN4A | MAPT 993/4885L3MBTL1 4835/4885MAPK1 1420/4885 |
| US-20030083317-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, CXCR1 | MAPT 4593/4885L3MBTL1 1853/4885MAPK1 816/4885 |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | MAPT 879/4885L3MBTL1 1961/4885MAPK1 3898/4885 |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | ABCC1, MGAT1, RRM2 | MAPT 4585/4885L3MBTL1 318/4885MAPK1 3177/4885 |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885L3MBTL1 539/4885MAPK1 2888/4885 |
| US-11065198-B2 | Dispersible compositions | VPS35, RAB35, RAB6A | MAPT 478/4885L3MBTL1 3932/4885MAPK1 2014/4885 |
| US-20030114472-A1 | Viricides | ZC3HAV1, ZC3HAV1L, POLR2H | MAPT 4504/4885L3MBTL1 186/4885MAPK1 3738/4885 |
| US-20080262007-A1 | Hiv Inhibiting 5-Substituted Pyrimidines | CBR1, RCOR1, CBR3 | MAPT 3851/4885L3MBTL1 1178/4885MAPK1 1114/4885 |
| US-20050192305-A1 | HIV inhibiting pyrimidine derivatives | NR4A1, CCR5, NR4A3 | MAPT 4739/4885L3MBTL1 2534/4885MAPK1 2881/4885 |
| US-20060142344-A1 | Method for treating HIV infection through co-administration of tipranavir and GW695634 | TIPARP, CD4, HDLBP | MAPT 556/4885L3MBTL1 1375/4885MAPK1 3611/4885 |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | MAPT 3375/4885L3MBTL1 2973/4885MAPK1 3393/4885 |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | MAPT 4242/4885L3MBTL1 539/4885MAPK1 2888/4885 |
| US-20040102456-A1 | Hiv inhibiting pyrazinone derivatives | SUB1, CCR5, CCR6 | MAPT 4660/4885L3MBTL1 1741/4885MAPK1 483/4885 |
| US-20080167296-A1 | 1,5,6,-Substituted-2-Oxo-3-Cyano-1,6a-Diaza-Tetrahydro-Fluoranthenes as Anti-Infective Agents | CYP2A7, CYP3A7, NEK7 | MAPT 4836/4885L3MBTL1 1488/4885MAPK1 2635/4885 |
| US-20180009819-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | COX6C, ZC3HAV1L, RRM2B | MAPT 4074/4885L3MBTL1 18/4885MAPK1 2969/4885 |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, NR4A1 | MAPT 4564/4885L3MBTL1 1979/4885MAPK1 676/4885 |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | RTF2, MCM6, SAMHD1 | MAPT 2365/4885L3MBTL1 654/4885MAPK1 2182/4885 |
| US-10072015-B2 | HIV inhibiting bicyclic pyrimidine derivatives | ZC3HAV1, CCR6, ZC3HAV1L | MAPT 4285/4885L3MBTL1 19/4885MAPK1 2737/4885 |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | NSUN2, CCNO, POLR2H | MAPT 4408/4885L3MBTL1 155/4885MAPK1 2725/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | MAPT 989/4885L3MBTL1 3637/4885MAPK1 1216/4885 |
| US-20080085907-A1 | Hiv Inhibiting Bicyclic Pyrimdine Derivatives | CCR6, CD4, CCNT1 | MAPT 4148/4885L3MBTL1 37/4885MAPK1 2785/4885 |
| US-20060160859-A1 | Method for treating HIV infection through co-administration of tipranavir and GW873140 | NAA40, TRIM25, CD4 | MAPT 704/4885L3MBTL1 1044/4885MAPK1 1763/4885 |
| US-20050197354-A1 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | HAVCR2, CBR1, NR4A1 | MAPT 4813/4885L3MBTL1 263/4885MAPK1 4276/4885 |
| US-20050288278-A1 | HIV replication inhibiting pyrimidines | NSUN2, POLR2H, CCNO | MAPT 4304/4885L3MBTL1 105/4885MAPK1 2260/4885 |
| US-20180244632-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885L3MBTL1 539/4885MAPK1 2888/4885 |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | REV1, CCNI, MCM6 | MAPT 1796/4885L3MBTL1 2507/4885MAPK1 2209/4885 |
| US-20160355519-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | COX6C, ZC3HAV1L, RRM2B | MAPT 4167/4885L3MBTL1 21/4885MAPK1 3034/4885 |
| US-20180016281-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | COX6C, ZC3HAV1L, CCR6 | MAPT 4087/4885L3MBTL1 14/4885MAPK1 2995/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | MAPT 4688/4885L3MBTL1 1435/4885MAPK1 3202/4885 |
| US-20110008434-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | CLIC4, HCN4, SCN4A | MAPT 993/4885L3MBTL1 4835/4885MAPK1 1420/4885 |
| US-20060135562-A1 | Method for treating HIV infection through co-administration of tipranavir and darunavir | SAMHD1, DARS1, APOBEC3A | MAPT 283/4885L3MBTL1 2975/4885MAPK1 4701/4885 |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | SAMHD1, NT5C2, TPMT | MAPT 3154/4885L3MBTL1 3345/4885MAPK1 3038/4885 |
| US-20180116964-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | SCN4A, PKD1, AFF4 | MAPT 724/4885L3MBTL1 4791/4885MAPK1 1952/4885 |
| US-20110150996-A1 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE | SCN4A, PKD1, AFF4 | MAPT 724/4885L3MBTL1 4791/4885MAPK1 1952/4885 |
| US-20080194602-A1 | Hiv Inhibiting 2-(4-Cyanophenylamino) Pyrimidine Oxide Derivatives | RTF2, SAMHD1, NUDT1 | MAPT 2856/4885L3MBTL1 979/4885MAPK1 1262/4885 |
| US-20040229847-A1 | Pyridinone and pyridinethione derivatives having hiv inhibiting properties | CYP2B6, CYP2S1, CYP2D6 | MAPT 4015/4885L3MBTL1 3774/4885MAPK1 916/4885 |
| US-20120190697-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | ZC3HAV1, CCR6, COX6C | MAPT 4320/4885L3MBTL1 17/4885MAPK1 2786/4885 |
| US-10077270-B2 | HIV inhibiting bicyclic pyrimidine derivatives | ZC3HAV1, CCR6, COX6C | MAPT 4320/4885L3MBTL1 17/4885MAPK1 2786/4885 |
| US-20060106043-A1 | Method for treating HIV infection through co-administration of tipranavir and etravirine | TMPRSS4, CYP3A7, CYP3A4 | MAPT 208/4885L3MBTL1 3213/4885MAPK1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.